• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ferrer Internacional S.A. - Product Pipeline Review - 2012 Product Image

Ferrer Internacional S.A. - Product Pipeline Review - 2012

  • ID: 2167241
  • June 2012
  • 86 pages
  • Global Markets Direct

Ferrer Internacional S.A. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Ferrer Internacional S.A. - Product Pipeline Review - 2012” provides data on the Ferrer Internacional S.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ferrer Internacional S.A.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ferrer Internacional S.A. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ferrer Internacional S.A. - Brief Ferrer Internacional S.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ferrer Internacional S.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline READ MORE >



List of Tables
List of Figures
Ferrer Internacional S.A. Snapshot
Ferrer Internacional S.A. Overview
Key Information
Key Facts
Ferrer Internacional S.A. – Research and Development Overview
Key Therapeutic Areas
Ferrer Internacional S.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ferrer Internacional S.A. – Pipeline Products Glance
Ferrer Internacional S.A. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Ferrer Internacional S.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Ferrer Internacional S.A. – Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Ferrer Internacional S.A. – Drug Profiles
Acetylsalicylic Acid + Simvastatin + Ramipril
Product Description
Mechanism of Action
R&D Progress
Arasertaconazole
Product Description
Mechanism of Action
R&D Progress
Egrifta
Product Description
Mechanism of Action
R&D Progress
GF-009549-00
Product Description
Mechanism of Action
R&D Progress
GF-011802-00
Product Description
Mechanism of Action
R&D Progress
GF-011806-00
Product Description
Mechanism of Action
R&D Progress
GF-013062-00
Product Description
Mechanism of Action
R&D Progress
GF-015646-00
Product Description
Mechanism of Action
R&D Progress
GF-015647
Product Description
Mechanism of Action
R&D Progress
GF-016469-00
Product Description
Mechanism of Action
R&D Progress
GF-016509-00
Product Description
Mechanism of Action
R&D Progress
T-3912
Product Description
Mechanism of Action
R&D Progress
Ferrer Internacional S.A. – Pipeline Analysis
Ferrer Internacional S.A. – Pipeline Products by Therapeutic Class
Ferrer Internacional S.A. – Pipeline Products By Target
Ferrer Internacional S.A. – Pipeline Products by Route of Administration
Ferrer Internacional S.A. – Pipeline Products By Mechanism of Action
Ferrer Internacional S.A. – Recent Pipeline Updates
Ferrer Internacional S.A. - Dormant Projects
Ferrer Internacional S.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Ferrer Internacional S.A., Deals Summary
Ferrer Internacional S.A., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Oryzon Secures $17 Million In Series B Round Of Financing
Partnerships
Alexza Pharma Enters Into Co-Marketing Agreement With Grupo Ferrer International For Adasuve
Laboratorios Farmaceuticos ROVI Announces Joint Venture With Ferrer
Hypha Discovery Enters Into Drug Discovery Agreement With Ferrer
NicOx Enters Into Option Agreement With Ferrer Internacional
Janus Developments, Grupo Ferrer Internacional And Bioingenium Form Joint Venture
OWL Genomics Enters Into Distribution Agreement With Ferrer inCode
Agendia Expands Distribution Agreement With Ferrer inCode
Histocell Enters Into Co-Development Agreement With Ferrer
DiaGenic Enters Into Distribution Agreement With Ferrer inCode
Ferrer inCode Enters Into An Agreement With bioTheranostics
AccuVein Signs Distribution Agreement With Grupo Ferrer Internacional
Grupo Ferrer Enters Into Co-Marketing Agreement With BioActor
Agendia Enters Into Distribution Agreement With Ferrer inCode
Agendia Signs An Agreement With Ferrer inCode
Ethypharm Enters Into An Co-Marketing Agreement With Grupo Ferrer
Vasogen Enters Into Agreement With Grupo Ferrer
NicOx Enters Into Co-Development Agreement With Grupo Ferrer
Andromaco Forms Joint Venture With Ferrer
Licensing Agreements
Theratechnologies Enters Into Licensing Agreement With Ferrer Internacional
APR Applied Pharma Research And Labtec Enter Into Licensing Agreement With Ferrer Internacional For Donepezil
Barrier Therapeutics Enters Into Licensing Agreement With Grupo Ferrer Internacional
Grupo Ferrer Enters Into Licensing Agreement With IVAX
Stiefel Labs Enters Into Licensing Agreement With Grupo Ferrer
NicOx Signs Licensing Agreement With Ferrer
LAB Pharma Enters Into Licensing Agreement With Grupo Ferrer Internacional
Acquisition
Grupo Ferrer Internacional Receives Approval From Spanish Competition Commission To Acquire 50% Stake In Alentia Biotech
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Ferrer Internacional S.A., Key Information
Ferrer Internacional S.A., Key Facts
Ferrer Internacional S.A. – Pipeline by Indication, 2012
Ferrer Internacional S.A. – Pipeline by Stage of Development, 2012
Ferrer Internacional S.A. – Monotherapy Products in Pipeline, 2012
Ferrer Internacional S.A. – Combination Treatment Modalities in Pipeline, 2012
Ferrer Internacional S.A. – Filed, 2012
Ferrer Internacional S.A. – Phase III, 2012
Ferrer Internacional S.A. – Phase II, 2012
Ferrer Internacional S.A. – Discovery, 2012
Ferrer Internacional S.A. – Pipeline By Therapeutic Class, 2012
Ferrer Internacional S.A. - Pipeline By Target, 2012
Ferrer Internacional S.A. – Pipeline By Route of Administration, 2012
Ferrer Internacional S.A. – Pipeline Products By Mechanism of Action, 2012
Ferrer Internacional S.A. – Recent Pipeline Updates, 2012
Ferrer Internacional S.A. - Dormant Developmental Projects,2012
Ferrer Internacional S.A., Other Locations
Ferrer Internacional S.A., Subsidiaries
Ferrer Internacional S.A., Deals Summary
Oryzon Secures $17 Million In Series B Round Of Financing
Alexza Pharma Enters Into Co-Marketing Agreement With Grupo Ferrer International For Adasuve
Laboratorios Farmaceuticos ROVI Announces Joint Venture With Ferrer
Hypha Discovery Enters Into Drug Discovery Agreement With Ferrer
NicOx Enters Into Option Agreement With Ferrer Internacional
Janus Developments, Grupo Ferrer Internacional And Bioingenium Form Joint Venture
OWL Genomics Enters Into Distribution Agreement With Ferrer inCode
Agendia Expands Distribution Agreement With Ferrer inCode
Histocell Enters Into Co-Development Agreement With Ferrer
DiaGenic Enters Into Distribution Agreement With Ferrer inCode
Ferrer inCode Enters Into An Agreement With bioTheranostics
AccuVein Signs Distribution Agreement With Grupo Ferrer Internacional
Grupo Ferrer Enters Into Co-Marketing Agreement With BioActor
Agendia Enters Into Distribution Agreement With Ferrer inCode
Agendia Signs An Agreement With Ferrer inCode
Ethypharm Enters Into An Co-Marketing Agreement With Grupo Ferrer
Vasogen Enters Into Agreement With Grupo Ferrer
NicOx Enters Into Co-Development Agreement With Grupo Ferrer
Andromaco Forms Joint Venture With Ferrer
Theratechnologies Enters Into Licensing Agreement With Ferrer Internacional
APR Applied Pharma Research And Labtec Enter Into Licensing Agreement With Ferrer Internacional For Donepezil
Barrier Therapeutics Enters Into Licensing Agreement With Grupo Ferrer Internacional
Grupo Ferrer Enters Into Licensing Agreement With IVAX
Stiefel Labs Enters Into Licensing Agreement With Grupo Ferrer
NicOx Signs Licensing Agreement With Ferrer
LAB Pharma Enters Into Licensing Agreement With Grupo Ferrer Internacional
Grupo Ferrer Internacional Receives Approval From Spanish Competition Commission To Acquire 50% Stake In Alentia Biotech

List of Figures
Ferrer Internacional S.A. – Pipeline by Indication, 2012
Ferrer Internacional S.A. – Pipeline by Stage of Development, 2012
Ferrer Internacional S.A. – Monotherapy Products in Pipeline, 2012
Ferrer Internacional S.A. – Combination Treatment Modalities in Pipeline, 2012
Ferrer Internacional S.A. – Pipeline By Therapeutic Class, 2012
Ferrer Internacional S.A. - Pipeline By Target, 2012
Ferrer Internacional S.A. – Pipeline By Route of Administration, 2012
Ferrer Internacional S.A. - Pipeline Products By Mechanism of Action, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos